top of page

LATEST NEWS

Get the latest updates from TNA Therapeutics on new research, helpful resources, company news and upcoming events. 

1 Nov 2021

Discovery of a novel anti-metastatic BCL3 inhibitor

Publication describing the identification and development of TNAT-101 parent compound

Discovery of a novel anti-metastatic BCL3 inhibitor
READ MORE

14 Sept 2021

TNA Therapeutics selected for Alderley Park development program

Out of over 100 applicants TNA Therapeutics was selected as 1 of the 3 projects to take part in the prestigious Alderney Park program led by experienced industry professionals.

TNA Therapeutics selected for Alderley Park development program
READ MORE

21 May 2018

The Proto-oncogene BCL3 induces immune checkpoint PD-L1 expression

BCL3 has been shown to directly regulate PD-L1 expression, providing evidence that TNAT-101 may synergize with I/O therapies

The Proto-oncogene BCL3 induces immune checkpoint PD-L1 expression
READ MORE

14 Sept 2014

Bcl3 selectively promotes metastasis of ErbB2-driven breast cancer

The development of antimetastatic drugs is an urgent healthcare priority for patients with cancer, because metastasis is thought to account for around 90% of cancer deaths.

Bcl3 selectively promotes metastasis of ErbB2-driven breast cancer
READ MORE
TNA_LOGO-01.png

SCIENCE

ABOUT

LEADERSHIP

NEWS
CONTACT

EMAIL
Information@tnatherapeutics.com

OFFICES

TNA Therapeutics Inc, New York

TNA Therapeutics Ltd, London

TNA Therapeutics Sarl, Lausanne

SUBSCRIBE

To receive the latest TNA non-confidential deck and get the latest updates from TNA Therapeutics on new research, news and upcoming events, leave your email below!

Thanks for submitting!

Targeting Cancer At The Root

Copyright © 2022-2023 TNA Therapeutics 

  • LinkedIn
bottom of page